The United States Food and Drug Administration (FDA) has approved United States-based Celgene's Inrebic (fedratinib) intended to treat adult patients with intermediate-two or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis, it was reported yesterday.
The product is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). It is a JAK2-selective inhibitor with higher potency for JAK2 over family members JAK1, JAK3 and TYK2. It decreased phosphorylation of signal transducer and activator of transcription (STAT3/5) proteins, inhibited cell proliferation and induced apoptotic cell death in cell models expressing mutationally active JAK2 or FLT3.
The product's development programme covers multiple studies, including Jakarta and Jakarta 2. The trials hired 608 patients, receiving more than one dose ranging from 30mg to 800mg, of whom 459 had myelofibrosis and around 97% treated with ruxolitinib. The phase three multicentre, randomised, double-blind and placebo-controlled trial evaluated the efficacy of once-daily oral doses of Inrebic compared with placebo in patients with intermediate-two or high-risk primary or secondary myelofibrosis and a platelet count of up to 50 x 10/9/L who were earlier untreated with a JAK inhibitor. The company said that the primary endpoint was spleen response rate.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study